Clinical Trial Update: A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for YY-20394 in relapsed or refractory peripheral T-cell/NK-cell lymphoma (PTCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• YY-20394

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: PTCL | Phase 2 | Status: UNKNOWN